Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159

NCT01681433 is registered in ClinicalTrials.gov with Costantine Albany as lead sponsor.

NCT NCT01681433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01681433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
Lead sponsor
Costantine Albany
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2012
Completion date
June 21, 2017
Enrollment
72 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castrate-resistant prostate cancer, prostate cancer, psa